Emerging Therapies for the Management of Metastatic Castration-Sensitive Prostate Cancer
| Overview / Abstract: |
Target Audience This activity is designed to meet the educational needs of medical oncologists, urologic oncologists, urologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with prostate cancer. Program Overview Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. This year, it is estimated that about 174,650 men in the United States will be diagnosed with prostate cancer and 31,620 men will die from this disease. Androgen deprivation therapy (ADT) aimed at lowering the level of androgens, is the standard of care for men with advanced prostate cancer. Newly diagnosed metastatic disease that has spread to other parts of the body and still responds to testosterone suppression therapy is called metastatic castration-sensitive prostate cancer (mCSPC). Androgen receptor inhibitors are currently being investigated in combination with ADT given the knowledge that deeper androgen signal inhibition results in further improved outcomes in mCSPC. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence and performance gaps exist in the optimal management of mCSPC among oncology practitioners. Participants from previous Association of Community Cancer Centers (ACCC) educational programs revealed transitions of care, including communication between the numerous healthcare settings (52%), side effect management (45%), and keeping current on the latest treatment modalities (29%) as among the most commonly encountered challenges for practitioners. This education activity will provide guidance on the optimal management of mCSPC to oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The educational program will address some of the challenges in optimal sequencing of care in mCSPC and will provide an opportunity to discuss with leading oncology experts and colleagues how new research clinical updates can be translated into new patient care strategies. Learning Objectives Upon completion of this activity, participants should be better able to: Describe current and emerging treatment options in mCSPC |
|
Expiration |
Jan 25, 2022 |
|
Discipline(s) |
Nursing CNE, Pharmacy CPE, Physician CME |
|
Format |
Online |
|
Credits / Hours |
1.0 AMA PRA Category 1 Credit(s)™ |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
Faculty Archana Ajmera, MSN, ANP-BC, AOCNP Archana Ajmera, MSN, is a board-certified adult nurse practitioner (ANP-BC) and an advanced oncology certified nurse practitioner (AOCNP). She is currently working as an NP at UC San Diego Health Moores Cancer Center and helps treat people with prostate cancer, renal cell carcinoma, urothelial carcinoma, testicular germ cell tumors and penile carcinoma. Her scope of practice includes collaborating with her physician colleagues in physical evaluations, diagnosis, treatment, symptom management, supportive care, and end of life care. Additionally, she is currently the Advanced Practice Provider Supervisor of Moores Cancer Center at UCSD Health. Prior to joining UC San Diego Health, Mrs. Ajmera was an oncology nurse practitioner at UC San Francisco, where she cared for adults with hematologic malignancies and bone marrow transplant candidates, as well as women receiving breast cancer treatment. She was also an oncology nurse practitioner at Massachusetts General Hospital in Boston, where she managed the care of women undergoing treatment with surgery and chemotherapy for gynecologic malignancies. Mrs. Ajmera is also a board-certified women’s health care nurse practitioner (WHNP-BC). She obtained a master’s degree in nursing from Massachusetts General Hospital Institute of Health Professions School of Nursing in Boston. She earned her bachelor’s degree in nutritional science from UC Berkeley. She is a member of the American Society of Clinical Oncology and National Comprehensive Cancer Network (NCCN). Pedro Barata, MD, MSc Dr. Pedro Barata earned his medical degree from the New University of Lisbon in 2009 and completed his medical oncology training in 2016. Subsequently, he was invited to join the genitourinary group at Taussig Cancer Center, where he worked as a clinical fellow in genitourinary malignancies. Dr. Barata then moved to Tulane University to continue his clinical and research work in the GU field. Dr Barata successfully expanded the genitourinary program offered at Tulane Cancer Center and he currently leads the kidney and bladder cancer program at Tulane University with a focus on clinical trials. Dr. Barata has authored or co-authored more than 60 research publications in high-quality journals, such as Cancer, Annals of Oncology, and CA: Cancer journal Clinicians, with more than 700 scientific citations. In addition, he has presented multiple abstracts at important national and international meetings and has won multiple prestigious awards, including the Scholar-in-Training Award, AACR-NCI-EORTC Triple Meeting (2017) and the Annual Accelerating Anticancer Agent Development and Validation (AAADV) Program Scholarship (2018). He serves as a reviewer for prestigious peer-reviewed journals, such as JAMA Oncology, ASCO and Journal Global Oncology and is a panel reviewer for Department of Defense Congressionally Directed Medical Research Programs (CDMRP) for genitourinary tumors. Erik Castle, MD, FACS Dr. Erik Castle is a Professor of Urology at Tulane University School of Medicine, specializing in urologic oncology surgery and minimally invasive/robotic surgery. Dr. Castle's surgical expertise includes robot-assisted radical cystectomy, prostatectomy, retroperitoneal lymph node dissection, and partial nephrectomy. He pioneered robot-assisted radical cystecomy in 2005 and robot-assisted RPLND in 2008 being one of the first surgeons in the world performing these surgeries at that time. Dr. Castle has demonstrated many of these procedures internationally and has published extensively across topics of urologic care and science. He serves on the Early Detection of Prostate Cancer Panel for the National Comprehensive Cancer Network (NCCN). He earned his medical degree from University of Texas, Southwestern Medical School. He completed Urology Residency at the University of Kansas Medical Center and followed with a Laparoscopic and Reconstructive Urologic Surgery fellowship at Mayo Clinic of Arizona. Dr. Castle's research focus includes prostate, bladder, testicular, and kidney cancers. He has experience in clinical trials, health sciences research, outcomes research, and basic science research. Lisa M. Holle, PharmD, BCOP, FHOPA Dr. Holle completed her Bachelor of Science in Pharmacy and post-baccalaureate Doctor of Pharmacy from the University of Wisconsin–Madison. She completed a specialized oncology residency at UT M.D. Anderson Cancer Center, and is a board-certified oncology pharmacist. Dr. Holle has worked as an oncology pharmacist for over 20 years in a variety of settings including private hospitals, academic medical centers, and medical communications. Currently, Dr. Holle is an Associate Clinical Professor at the UConn School of Pharmacy and Associate Professor at the UConn School of Medicine. Her practice site is at the UConn Health Carole and Ray Neag Comprehensive Cancer Center, where she works in a team-based ambulatory care clinic focusing on genitourinary and gastrointestinal cancers and in another team based-clinic focusing on hematologic malignancies. Dr. Holle is a Past President of HOPA and a past Secretariat member and Treasurer of the International Society of Oncology Pharmacy Practitioners (ISOPP). She is also an active member in many other professional oncology and pharmacy organizations. Dr. Holle’s clinical research program focuses on numeracy and patient decision-making, oncology quality improvement initiatives, medical marijuana, and oral anticancer therapy management. She has authored numerous articles and chapters on oncology and teaching-related topics. |
|
Sponsors / Supporters / Grant Providers |
Astellas and Pfizer, Inc. |
|
Keywords / Search Terms |
Relias LLC Relias LLC., FREE CME., Metastatic Castration-Sensitive Prostate Cancer Free CE CME |
|